StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Aastha Jain, Hem Securities

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byAastha Jain, Hem SecuritiesHorizon: NA (inferred Intraday)14 Oct 2026, 8:46 am ISTvia Zee Business (Live)

Entry₹1,230Stated
Target₹1,260
Total upside +2.44% (call closed)
Stop loss₹1,190-3.25% risk
At expiry₹1,211.614 Oct 2026, 3:05 pm
Expired-1.50%
Follow Aastha Jain for new calls(21% target hit, 61 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 14 Oct 2026
0 supporting4 opposing
Supports the BUY call (0)

Nothing found in this tip’s window yet.

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (4)

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 4d ago

(opens in new tab)

A pre-approval inspection ends with USFDA observations at Dr. Reddy’s (RDY).

NewsGoogle News·8 Oct · 5d ago

(opens in new tab)

Dr. Reddy's USFDA PAI Inspection: Form 483 at FTO-11 Plant

NewsGoogle News·8 Oct · 5d ago

(opens in new tab)

Pomerantz LLP investigates Dr. Reddy's over semaglutide-linked losses

NewsGoogle News·8 Oct · 6d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Aastha Jain, Hem Securities

Every call and its outcome